Fig. 7. CCL7 enhances the efficacy of anti-PD-1 checkpoint immunotherapy in KP mice.

a A scheme of combinational therapy of CCL7 and anti-PD-1. KP mice were intranasally injected with Ad-Cre (2 × 10⁶ pfu/mouse) for 5 weeks, followed by intranasal injection of Lenti-Vec or Lenti-CCL7 and intraperitoneal injection of control isotype lgG or anti-PD-1 antibody twice a week for 4 weeks. b Survival of KP (n = 15, 14, or 15 for Vec + IgG, Vec+anti-PD-1 or CCL7 + anti-PD-1, respectively) mice treated as in a. c IHC staining of sections (upper images) and tumor area (lower left graph) and size (lower right graph) analysis of tumor-burdened lungs of KP mice (n = 8, 10, or 11 for Vec + IgG, Vec + anti-PD-1 or CCL7 + anti-PD-1, respectively) treated as in a. d, e IHC staining (d) and intensity analysis (e) of CD11c, XCR1, CD8, and CCL7 in tumor sections of KP (n = 8, 10, or 11 for Vec + IgG, Vec + anti-PD-1 or CCL7 + anti-PD-1, respectively) mice treated as in a. Scale bars represent 500 μm. Log-rank analysis (b) or two-tailed student’s t-test (c, e). Scale bars, 5 mm (c), 50 μm (d), respectively. Graphs show mean ± SEM (c, e). Data are combined results of three independent experiments. Source data are provided as a source data file.